Norwich Pharmaceuticals, Inc. has formed Norwich Clinical Services to provide clinical testing capabilities to expand the company’s third party services. The Clinical Services division will offer a complete range of clinical research capabilities including Phase I – IV trials, bioanalytical studies and pharmacovigilance monitoring services.

“The introduction of Norwich Clinical Services underscores our strategic focus to provide customers with a comprehensive solution for all stages of product life cycle management,” said Doug Drysdale, chief executive officer of Alvogen, a company that includes Norwich Pharmaceuticals and Norwich Clinical Services. “We have assembled the highest level of professional expertise to ensure Norwich Clinical Services matches our tradition of unparalleled quality standards and delivers contract pharmaceutical services with everyday excellence.”

Dr. Saral Thangam, M.D., Ph.D., will serve as managing director of Norwich Clinical Services. She will lead an experienced team of professionals who each have 15 years experience in clinical research and life sciences. Prior to joining Norwich, Dr. Thangam was the managing director of Lotus Labs.

Additional leadership positions for Norwich Clinical Services will include Sudhir Pai, director, and Dr. Fjalar Kristjansson, Ph.D., technical director. The new division expects to employ approximately 100 staff during the next 12 months, including physicians, nurses, biostatisticians, quality assurance and bioanalytical specialists, medical writers and pharmacokineticists.

Initially the Clinical Services division will offer pharmacovigilance monitoring supported by Oracle AERS software, bioanalytical studies utilizing API 4000 LC/MS systems, and medical writing services. An independent, 60-bed, clinical trial facility will open later this year with the capability to conduct pharmacokinetics in healthy volunteers, bioavailability and bioequivalence studies, drug metabolism studies, dose proportionality studies and multiple dose studies.


Click here to learn more about Norwich Pharmaceuticals